Persistent Asset Partners LTD Arcus Biosciences, Inc. Transaction History
Persistent Asset Partners LTD
- $121 Billion
- Q4 2024
A detailed history of Persistent Asset Partners LTD transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Persistent Asset Partners LTD holds 50,213 shares of RCUS stock, worth $550,334. This represents 0.54% of its overall portfolio holdings.
Number of Shares
50,213Holding current value
$550,334% of portfolio
0.54%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
201Shares Held
51.2MCall Options Held
288KPut Options Held
138K-
Black Rock Inc. New York, NY9.76MShares$107 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.39MShares$59.1 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.52MShares$38.6 Million0.39% of portfolio
-
State Street Corp Boston, MA2.99MShares$32.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2MShares$21.9 Million0.07% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $791M
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...